Company intelligence
EpilepsyGTx
Our mission is to make patients with focal refractory epilepsy seizure-free
Biotechnology Research
Cambridge, GB
9 employees
2 public signals
About EpilepsyGTx
EpilepsyGTx is a late preclinical-stage biotech developing cutting-edge gene therapies that will transform the management of focal refractory epilepsy (FRE).
Verified activity
Signals from EpilepsyGTx
2 published signals
Research & Knowledge
EpilepsyGTx published an article titled 'Novel treatments for drug-resistant epilepsy: from polypharmacy to multimodality' discussing challenges and opportunities in the treatment of refractory epilepsy.
Reported by EpilepsyGTx
Research & Knowledge
EpilepsyGTx announced that EPY201, its lead gene therapy candidate, has the potential to transform outcomes for 10 million people living with focal refractory epilepsy globally.
Reported by EpilepsyGTx